Copaxone survives attack by Mylan in Dutch Court

Copaxone2

The District Court of the Hague (Netherlands) has rejected a patent revocation suit brought by Mylan B.V., a subsidiary of Mylan Laboratories Inc., against the patent covering Copaxone, a treatment for Multiple Schlorosis that is patented by Teva Pharmaceutical Industries Ltd. The Dutch court upheld the validity of Teva’s European Patent, which will remain in force until May 2015. The favorable ruling follows a similar ruling by the English Court of Appeal in July 2013, which also affirmed the validity of Teva’s patent.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: